YWYafeng Wang

Yafeng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yafeng Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Pengju Wang

    Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China

    3 shared publications
  • Bin Du

    Zhengzhou University

    1 shared publication
  • Dandan Wang

    Sino‐British Research Centre for Molecular Oncology National Centre for International Research in Cell and Gene Therapy State Key Laboratory of Esophageal Cancer Prevention & Treatment School of Basic Medical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China

    1 shared publication
  • Fan Zhang

    Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Metabolic Dysregulation & the Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, China

    1 shared publication
  • Huihui Sun

    Sino‐British Research Centre for Molecular Oncology National Centre for International Research in Cell and Gene Therapy State Key Laboratory of Esophageal Cancer Prevention & Treatment School of Basic Medical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China

    1 shared publication
  • Jinjin Shi

    School of Pharmaceutical Sciences Zhengzhou University Zhengzhou China

    1 shared publication

Latest Publications

  • Open Access

    Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy

    by Lihua Xu, Mingzheng Peng, Tingting Gao, Dandan Wang, Xiaowu Lian, Huihui Sun, Jinjin Shi, Yafeng Wang, Pengju Wang

    Endogenous essential metal ions play an important role in many life processes, especially in tumor development and immune response. The approval of various metallodrugs for tumor therapy brings more attention to the antitumor effect of metal ions. With the deepening understanding of the regulation mechanisms of metal ion homeostasis in vivo, breaking intracellular metal ion homeostasis becomes a new means to inhibit the proliferation of tumor cells and activate antitumor immune response. Diverse nanomedicines with the loading of small molecular ion regulators or metal ions have been developed to disrupt metal ion homeostasis in tumor cells, with higher safety and efficiency than free small molecular ion regulators or metal compounds. This comprehensive review focuses on the latest progress of various intracellular metal ion homeostasis regulation‐based nanomedicines in tumor therapy including calcium ion (Ca2+), ferrous ion (Fe2+), cuprous ion (Cu+), managanese ion (Mn2+), and zinc ion (Zn2+). The physiological functions and homeostasis regulation processes of ions are summarized to guide the design of metal ion regulation‐based nanomedicines. Then the antitumor mechanisms of various ions‐based nanomedicines and some efficient synergistic therapies are highlighted. Finally, the challenges and future developments of ion regulation‐based antitumor therapy are also discussed, hoping to provide a reference for finding more effective metal ions and synergistic therapies.


  • Open Access

    The capability of heterogeneous γδ T cells in cancer treatment

    by Wenyi Yan, Louisa S. Chard Dunmall, Nicholas R. Lemoine, Yaohe Wang, Yafeng Wang, Pengju Wang

    γδ T cells, a specialized subset of T lymphocytes, have garnered significant attention within the realm of cancer immunotherapy. Operating at the nexus between adaptive and innate immunological paradigms, these cells showcase a profound tumor discernment repertoire, hinting at novel immunotherapeutic strategies. Significantly, these cells possess the capability to directly identify and eliminate tumor cells without reliance on HLA-antigen presentation. Furthermore, γδ T cells have the faculty to present tumor antigens to αβ T cells, amplifying their anti-tumoral efficacy.Within the diverse and heterogeneous subpopulations of γδ T cells, distinct immune functionalities emerge, manifesting either anti-tumor or pro-tumor roles within the tumor microenvironment. Grasping and strategically harnessing these heterogeneous γδ T cell cohorts is pivotal to their integration in tumor-specific immunotherapeutic modalities. The aim of this review is to describe the heterogeneity of the γδ T cell lineage and the functional plasticity it generates in the treatment of malignant tumors. This review endeavors to elucidate the intricate heterogeneity inherent to the γδ T cell lineage, the consequential functional dynamics in combating malignancies, the latest advancements from clinical trials, and the evolving landscape of γδ T cell-based oncological interventions, while addressing the challenges impeding the field.